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The bias of Cases Journal is to publish unless there are
strong reasons why we can't. Bruce Arroll and colleagues
tell an interesting story[1] of how neighbours helped two
couples conduct single patient trials to determine whether
their babies had milk allergy. The story is informative and
well told but raises several problems, most of them ethi-
cal, that we've had to think through before publishing.
Firstly, the authors have no consent for publication from
the patients. I spent years struggling with the problem of
patient consent when I was editor of the BMJ, and we
moved from a position like all other journals of never
seeking consent to insisting on consent in all cases. The
latter proved to be too extreme a position, particular for
anecdotes from years ago – which we published in the
BMJ and were popular. BMJ policy now requires four con-
ditions to be met for a story to be told about a patient
without consent. The conditions are:
a) The patient is dead and his or her family is untraceable
to seek consent from
(b) The article contains a worthwhile clinical lesson or
public health point which could not be as effectively
made in any other way.
(c) A reasonable person in the position of the patient's rel-
atives would not be expected to object to the publication
of the case.
(d) The risk of identification of the patient is minimised
by measures designed to prevent the identity of the
patient being revealed either to others or to the patient's
relatives.
It's most unlikely that either the parents or the babies are
dead – so the first condition is not met. The article makes
an excellent point, but it could probably be made in
another way – and possibly has been. So we can't be con-
fident that the second condition is met. The third and
fourth conditions are, however, met handsomely, and I
find it very hard to imagine the parents or the babies being
upset by publication of this report – even in the highly
unlikely event that they could be recognised. I'm thus
happy to publish despite all four conditions not being
met.
A second problem is that the babies were given soya-based
milk on unconvincing grounds and could have suffered
an anaphylactic reaction. The reviewer raised this point,
and the authors acknowledge the risk – but dismiss it as
small. The patients didn't suffer an anaphylactic reaction,
and it would seem absurdly heavy handed to decline to
publish an interesting story in unknown patients on the
grounds that the patients ran a small risk 20 years ago.
A third problem is that we have lots of missing data. We
can't see the charts of when the babies were given the dif-
ferent milks and how the timings related to the pattern of
symptoms. Nor do we have any follow up data on the
babies. We don't even know if the baby who did appear to
have cow's milk allergy did better when cow's milk was
removed from the child's diet. Nor do we even know the
genders of the babies. It would be good to know all of
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these things, but I judge that the story still has interest and
importance without those details.
Fourthly, the doctor conducted an experiment in two
babies without consent from an ethics committee (or
institutional review board). Can this be acceptable? Did
the parents understand that there babies were included in
a experiment? They must have done: the whole point of
the exercise was that it was an experiment. The reality of
20 years ago in most, perhaps all, countries is that there
were no ethics committees for primary care research.
Indeed, there wasn't much research in primary care. So
again it would seem slightly absurd to decline to publish
the paper because of the failure to get ethics committee
approval.
But what if a doctor were to want to conduct such a trial
today? Should he or she go ahead without ethics commit-
tee approval? Gordon Guyatt, one of the authors of the
study, has tackled this questions with others. [2] They
argue that if the study is undertaken as part of clinical
practice then there is no need for consent from an ethics
committee, but the doctors should ensure that the
patients understand fully what is happening and get writ-
ten consent. If, however, the study us undertaken as part
of research then approval from an ethics committee is
essential.
I'm uncertain exactly how you tell whether something is
conducted for clinical or research reasons – perhaps the
distinction is that one is conducted for the benefit of the
patients and the other more for the benefit of the broader
community. This doesn't seem to me to be an entirely
clear distinction, especially if, as in this case, an experi-
ment conducted for clinical reasons is published.
I can only think that it would be wise to contact the chair
of the local committee. Ethics committees famously vary
in their judgements. I tend to agree with Guyatt and col-
leagues that an N of 1 trial that is happening as part of rou-
tine practice would not need consent from an ethics
committee. The patients should, of course, give fully
informed consent – preferably in writing – but the nature
of much of medical practice is that doctors and patients
are constantly "experimenting" to discover, for example,
"whether time will sort this out" or "whether this drug
might work better than the one you are on at the
moment." It would be clearly impractical to consult an
ethics committee over every such experiment. The differ-
ences with the "experiments" described here are that they
are being published and ironically are well designed –
with randomisation and controls. They thus feel much
more like experiments than the experiments that happen
every day in many meetings between doctors and patients.
So this paper not only tells an interesting story attractively
but has also thrown up enough questions to prompt an
editorial longer than the paper – for which perhaps I
ought to apologise.
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